Quantum BioPharma Ltd. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
QNTM Nasdaq 2830 www.quantumbiopharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Quantum BioPharma Ltd.

Quantum BioPharma Ltd. Announces Filing of Supplement to Management Information Circular Correcting Fractional Share Treatment Under Proposed Share Consolidation and Clarifies MVS Voting Power Threshold - Nov 5th, 2026 3:00 pm
Quantum BioPharma (QNTM) Advances Broad Strategy Anchored by Science, Disciplined Growth - Nov 5th, 2026 1:00 pm
Quantum BioPharma (QNTM) Draws 'Men's Fitness' Spotlight as Unbuzzd Trial Shows Early Promise - Nov 3rd, 2026 1:30 pm
Quantum BioPharma (QNTM) Featured in Men's Fitness Article Examining Unbuzzd Clinical Trial Results - Oct 20th, 2026 12:30 pm
Quantum BioPharma’s Phase 2 Shows Where Biotech Value Actually Gets Built - Oct 14th, 2026 7:50 am
Why Thermo Fisher Scientific (TMO) Is Back In The Spotlight - Oct 8th, 2026 8:08 am
World Renowned Law Firm Grant & Eisenhofer Appointed Lead Counsel In Newly Consolidated Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares - Oct 8th, 2026 6:00 am
Quantum BioPharma (QNTM) Enlists Thermo Fisher's Clinical Research Business to Launch Phase 2 Lucid-MS Trial - Oct 7th, 2026 1:30 pm
Quantum BioPharma (QNTM) Enters Study Start-Up Agreement for Lucid-MS Phase 2 Trial - Oct 6th, 2026 1:00 pm
Quantum BioPharma Signs Contract with Thermo Fisher Scientific’s Clinical Research Business to Implement Phase 2 Lucid-MS Trial in Multiple Sclerosis - Oct 6th, 2026 4:00 am
EXCLUSIVE: Thermo Fisher To Support Quantum Biopharma in Progressive Multiple Sclerosis Drug Trial - Oct 6th, 2026 3:48 am
IBN Announces Latest Episode of The BioMedWire Podcast Featuring the Return of Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. - Sep 30th, 2026 6:00 am
Quantum BioPharma (QNTM) Receives FDA Green Light to Move Lucid-MS Into Phase 2 Testing - Sep 25th, 2026 1:00 pm
Quantum Biopharma Licensee Unbuzzd Wellness to Advance Clinically Validated Alcohol Metabolism Accelerant After Appointing Zappy as CEO - Sep 24th, 2026 6:00 am
Quantum BioPharma (QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments - Sep 23rd, 2026 12:30 pm
Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target - Sep 17th, 2026 6:00 am
Quantum BioPharma (QNTM) to Present at 3rd Annual ArcStone-Kingswood Growth Summit - Sep 15th, 2026 1:30 pm
Quantum BioPharma to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto - Sep 15th, 2026 6:00 am
Quantum BioPharma Ltd. (NASDAQ: QNTM) Filling Key Gap in MS Treatment, Cleared by FDA to Launch Historic Trials - Sep 11th, 2026 6:30 am